Chinese guidelines for evidence-based evaluation of off-label drug use in ophthalmology

Title: Chinese guidelines for evidence-based evaluation of off-label drug use in ophthalmology
Edition: Original
Classification: Standard guideline
Field: Treatment
Countries and regions: China
Guidelines users:
Evidence classification method: Grading of Recommendations, Assessment, Development and Evaluations, GRADE
Development unit: 中国药学会医院药学专业委员会;首都医科大学附属北京同仁医院
Registration time: 2021-04-19
Registration number: IPGRP-2021CN096
Purpose of the guideline: Off-label drug use in ophthalmology is widespread in different medical institutions in China. However, there are only scattered studies evaluating its effectiveness and safety, and no unified conclusion has been reached yet. We plan to systematically evaluate the rationality of current off-label drug use in domestic medical institutions in order to develop evidence-based evaluation guidelines for off-label drug use in ophthalmology in China, so as to provide evidence support for rational drug use in ophthalmology and promote safe and correct drug use.